Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research - PubMed

Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research

N Rotman et al. Br J Surg. 1994 Jan.

Abstract

The records of 66 patients with histologically proven adenocarcinoma of the duodenum were reviewed retrospectively to determine factors influencing survival. The parameters studied were age, sex, weight loss, jaundice, anaemia, duodenal stenosis, type of surgical procedure, tumour size and location, depth of parietal invasion, presence and location of lymph node metastases, and pancreatic invasion. These factors were assessed in a group of 46 patients who underwent curative resection of the tumour; 20 patients who received palliative procedures were excluded from statistical analysis. Survival curves were established by the Kaplan-Meier method and compared by the Mantel-Haentszel test. The actuarial 3- and 5-year survival rates of patients undergoing curative resection were 59 and 45 per cent respectively. None of the prognostic factors studied influenced survival. These results indicate that resection of adenocarcinoma of the duodenum should be performed whenever possible, even in the presence of lymph node metastasis and pancreatic spread.

Similar articles

• What prognostic factors are important in duodenal adenocarcinoma?

  Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, Farley DR, van Heerden JA, Wiersema LM, Schleck CD, Donohue JH. Bakaeen FG, et al. Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2. doi: 10.1001/archsurg.135.6.635. Arch Surg. 2000. PMID: 10843358

• Prognostic Factors and Clinical Characteristics of Patients with Primary Duodenal Adenocarcinoma: A Single-Center Experience from China.

  Jiang QL, Huang XH, Chen YT, Zhang JW, Wang CF. Jiang QL, et al. Biomed Res Int. 2016;2016:6491049. doi: 10.1155/2016/6491049. Epub 2016 Dec 27. Biomed Res Int. 2016. PMID: 28116301 Free PMC article.

• Long-term outcomes in patients with duodenal adenocarcinoma.

  Lee SY, Lee JH, Hwang DW, Kim SC, Park KM, Lee YJ. Lee SY, et al. ANZ J Surg. 2014 Dec;84(12):970-5. doi: 10.1111/ans.12112. Epub 2013 May 8. ANZ J Surg. 2014. PMID: 23656271

• Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct.

  Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M, Block GE. Michelassi F, et al. Ann Surg. 1989 Oct;210(4):544-54; discussion 554-6. doi: 10.1097/00000658-198910000-00015. Ann Surg. 1989. PMID: 2679459 Free PMC article. Review.

• [Results of surgical therapy of primary adenocarcinoma of the duodenum].

  Lang H, Nadalin S, Raab R, Jähne J. Lang H, et al. Chirurg. 1999 May;70(5):571-7. doi: 10.1007/s001040050688. Chirurg. 1999. PMID: 10412601 Review. German.

Cited by

• Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.

  Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Zenali M, et al. Hum Pathol. 2013 Dec;44(12):2792-8. doi: 10.1016/j.humpath.2013.07.030. Epub 2013 Oct 15. Hum Pathol. 2013. PMID: 24139211 Free PMC article.

• Adenocarcinoma of the fourth portion of duodenum presenting as intussusception: an unusual manifestation of rare pathology.

  Varshney VK, Varshney B, Khera S, Sureka B. Varshney VK, et al. BMJ Case Rep. 2021 Jul 14;14(7):e244034. doi: 10.1136/bcr-2021-244034. BMJ Case Rep. 2021. PMID: 34261636 Free PMC article.

• Primary duodenal carcinoma.

  Adedeji OA, Trescoli-Serrano C, Garcia-Zarco M. Adedeji OA, et al. Postgrad Med J. 1995 Jun;71(836):354-8. doi: 10.1136/pgmj.71.836.354. Postgrad Med J. 1995. PMID: 7644397 Free PMC article.

• Prognostic factors for primary duodenal adenocarcinoma.

  Lee HG, You DD, Paik KY, Heo JS, Choi SH, Choi DW. Lee HG, et al. World J Surg. 2008 Oct;32(10):2246-52. doi: 10.1007/s00268-008-9678-6. World J Surg. 2008. PMID: 18668288

• The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.

  Crawley C, Ross P, Norman A, Hill A, Cunningham D. Crawley C, et al. Br J Cancer. 1998 Aug;78(4):508-10. doi: 10.1038/bjc.1998.523. Br J Cancer. 1998. PMID: 9716035 Free PMC article. Clinical Trial.

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems
  • Wiley

• Medical

  • MedlinePlus Health Information